Change Agents (CHGA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Aug, 2026Executive summary
Special meeting scheduled for October 8, 2026, to vote on 14 proposals, primarily related to equity issuances and capital structure adjustments.
Board unanimously recommends voting in favor of all proposals to support capital raising and operational flexibility.
Proposals are designed to comply with Nasdaq Listing Rule 5635(d) and ensure access to additional working capital.
Voting matters and shareholder proposals
Approval sought for issuance of common stock under an Equity Purchase Agreement with Hudson Global Ventures, up to $10 million at $0.20 per share.
Approval for issuance of 925,925 shares upon exercise of a warrant to Hudson Global Ventures.
Approval for future issuances of up to 250 million shares and warrants, with a maximum $100 million raise, at up to 80% discount to market, by April 8, 2027.
Approval for conversion of two promissory notes (February 11 and 19, 2026) into common stock, each with principal of $233,910, at a 25% discount to market price upon default.
Approval for issuance of 360,000 shares for forbearance on a prior loan, and for various consulting agreements totaling 1.85 million shares.
Approval for issuance of 1,000,000 shares via pre-funded warrants and 300,000 shares under a most-favored-nations provision.
Proposal to amend the certificate of incorporation to increase authorized common stock from 100 million to 125 million shares.
Adjournment proposal allows the meeting to be postponed to solicit additional proxies if needed.
Board of directors and corporate governance
Board of directors and executive officers do not have personal interests in any of the proposals.
Security ownership table provided for directors, officers, and major shareholders.
Procedures for shareholder proposals and director nominations for the 2027 annual meeting are outlined.
Latest events from Change Agents
- Early-stage AI and health tech firm seeks funding via dilutive equity line amid ongoing losses and risks.CHGA
Registration filing - All proposals, including director elections and a reverse stock split, were approved.CHGA
AGM 2026 - Net loss narrowed sharply, but liquidity and Nasdaq compliance risks remain elevated.CHGA
Q2 2026 - Stockholders will vote on equity issuances, note conversions, and a charter amendment to increase authorized shares.CHGA
Proxy filing - AI and health tech firm registers 35.6M shares for resale amid ongoing losses and capital needs.CHGA
Registration filing - Net loss from continuing operations surged to $17.5M in 2025 amid a strategic pivot to AI and health tech.CHGA
Q4 2025 - AI and health tech pivot faces major losses, cash shortfall, and high dilution risk in new offering.CHGA
Registration filing - Net loss widened to $2.48M on higher expenses; going concern risk remains significant.CHGA
Q1 2025 - Q3 rental revenue rose and losses narrowed, but liquidity and going concern risks persist.CHGA
Q3 2025